H. Lundbeck A/S ended the first nine months of 2019 with two acquisitions under its belt and an increase in revenue from four key medicines for neurological disorders. Total revenue for the period was DKK 12.6 billion (€1.7 billion) of which 53% was attributed to the four medicines. However group revenue was down by 9% from a year earlier due to loss of patent protection for Onfi, a treatment for Lennox-Gastaut syndrome.

A new drug for anaemia in patients with beta thalassaemia, a rare blood disorder, has been approved for marketing in the US following clinical testing which showed that patients receiving the treatment needed fewer blood transfusions than those on a placebo. The drug, Reblozyl (luspatercept-aamt), was authorised by the Food and Drug Administration on 8 November.